122 related articles for article (PubMed ID: 7289632)
21. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets.
Patscheke H; Stegmeier K
Thromb Res; 1984 Feb; 33(3):277-88. PubMed ID: 6424261
[TBL] [Abstract][Full Text] [Related]
22. Succinate potentiates the action of platelet agonists.
Huang EM; McGowan EB; Detwiler TC
Thromb Res; 1984 Oct; 36(1):1-8. PubMed ID: 6095483
[TBL] [Abstract][Full Text] [Related]
23. Extracellular ATP inhibits agonist-induced mobilization of internal calcium in human platelets.
Soslau G; McKenzie RJ; Brodsky I; Devlin TM
Biochim Biophys Acta; 1995 Jul; 1268(1):73-80. PubMed ID: 7626665
[TBL] [Abstract][Full Text] [Related]
24. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to guinea-pig platelets.
Halushka PV; Mais DE; Garvin M
Eur J Pharmacol; 1986 Nov; 131(1):49-54. PubMed ID: 3816947
[TBL] [Abstract][Full Text] [Related]
25. Prostaglandins and human platelet aggregation. Implications for the anti-aggregating activity of thromboxane-synthase inhibitors.
Rajtar G; Cerletti C; Castagnoli MN; Bertelé V; de Gaetano G
Biochem Pharmacol; 1985 Feb; 34(3):307-10. PubMed ID: 3918536
[TBL] [Abstract][Full Text] [Related]
26. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
Johnson GJ; Leis LA; Francis GS
Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
[TBL] [Abstract][Full Text] [Related]
27. Characterization of the inhibition of U46619-mediated human platelet activation by the trimetoquinol isomers. Evidence for endoperoxide/thromboxane A2 receptor blockade.
Ahn CH; Romstedt KJ; Wallace LJ; Miller DD; Feller DR
Biochem Pharmacol; 1988 Aug; 37(15):3023-33. PubMed ID: 3134894
[TBL] [Abstract][Full Text] [Related]
28. Differential ability of agonists to express distinct pools of fibrinogen (GpIIb/IIIa) receptors which can mediate the aggregation of human platelets.
Watts IS; Keery RJ; Lumley P
Thromb Haemost; 1989 Nov; 62(3):955-61. PubMed ID: 2512682
[TBL] [Abstract][Full Text] [Related]
29. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets.
Radomski MW; Palmer RM; Moncada S
Br J Pharmacol; 1987 Sep; 92(1):181-7. PubMed ID: 3311265
[TBL] [Abstract][Full Text] [Related]
30. Effect of phorbol 12-myristate 13-acetate (PMA) on agonist-induced arachidonate release and 5-hydroxytryptamine secretion in human platelets. Dependence of effects on agonist type and time of incubation with PMA.
Krishnamurthi S; Joseph S; Kakkar VV
Biochim Biophys Acta; 1987 Mar; 927(3):429-36. PubMed ID: 3101746
[TBL] [Abstract][Full Text] [Related]
31. Effects of any epoxymethano stable analogue of prostaglandin endoperoxides (U-46619) on human platelets.
di Minno G; Bertelé V; Bianchi L; Barbieri B; Cerletti C; Dejana E; de Gaetano G; Silver MJ
Thromb Haemost; 1981 Apr; 45(2):103-6. PubMed ID: 6266066
[TBL] [Abstract][Full Text] [Related]
32. Removal of extraplatelet Na+ eliminates indomethacin-sensitive secretion from human platelets stimulated by epinephrine, ADP, and thrombin.
Connolly TM; Limbird LE
Proc Natl Acad Sci U S A; 1983 Sep; 80(17):5320-4. PubMed ID: 6577431
[TBL] [Abstract][Full Text] [Related]
33. The potentiation of phorbol ester-induced aggregation of human platelets by the prostaglandin endoperoxide analogue, U46619.
Edwards MC; Williamson EM; Evans FJ
J Pharm Pharmacol; 1987 May; 39(5):370-7. PubMed ID: 2886585
[TBL] [Abstract][Full Text] [Related]
34. Platelet hypersensitivity in cholesterol-fed rabbits: enhancement of thromboxane A2-dependent and thrombin-induced, thromboxane A2-independent platelet responses.
Gross PL; Rand ML; Barrow DV; Packham MA
Atherosclerosis; 1991 May; 88(1):77-86. PubMed ID: 1878012
[TBL] [Abstract][Full Text] [Related]
35. Role of protein kinase C in U46619-induced platelet shape change, aggregation and secretion.
Nakano T; Hanasaki K; Arita H
Thromb Res; 1989 Oct; 56(2):299-306. PubMed ID: 2617470
[TBL] [Abstract][Full Text] [Related]
36. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
37. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function.
Murray KJ; England PJ; Hallam TJ; Maguire J; Moores K; Reeves ML; Simpson AW; Rink TJ
Br J Pharmacol; 1990 Mar; 99(3):612-6. PubMed ID: 2158847
[TBL] [Abstract][Full Text] [Related]
38. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets.
Ohkubo S; Nakahata N; Ohizumi Y
Br J Pharmacol; 1996 Mar; 117(6):1095-104. PubMed ID: 8882602
[TBL] [Abstract][Full Text] [Related]
39. Phenol red is a thromboxane A2/prostaglandin H2 receptor antagonist in canine lingual arteries and human platelets.
Greenberg SS; Johns A; Kleha J; Xie J; Wang Y; Bianchi J; Conley K
J Pharmacol Exp Ther; 1994 Mar; 268(3):1352-61. PubMed ID: 8138950
[TBL] [Abstract][Full Text] [Related]
40. The binding of [3H]9,11-dideoxy,9 alpha-11 alpha-methanoepoxy prostaglandin F2 alpha (U 46619) to washed human platelets.
Jaschonek K; Faul C; Weisenberger H; Schmidt H; Renn W
Prog Clin Biol Res; 1989; 301():327-33. PubMed ID: 2529551
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
